Author:
Ontiveros-Padilla Luis,Batty Cole J.,Hendy Dylan A.,Pena Erik S.,Roque John A.,Stiepel Rebeca T.,Carlock Michael A.,Simpson Sean R.,Ross Ted M.,Abraham Soman N.,Staats Herman F.,Bachelder Eric M.,Ainslie Kristy M.
Abstract
Currently licensed vaccine adjuvants offer limited mucosal immunity, which is needed to better combat respiratory infections such as influenza. Mast cells (MCs) are emerging as a target for a new class of mucosal vaccine adjuvants. Here, we developed and characterized a nanoparticulate adjuvant composed of an MC activator [mastoparan-7 (M7)] and a TLR ligand (CpG). This novel nanoparticle (NP) adjuvant was co-formulated with a computationally optimized broadly reactive antigen (COBRA) for hemagglutinin (HA), which is broadly reactive against influenza strains. M7 was combined at different ratios with CpG and tested for in vitro immune responses and cytotoxicity. We observed significantly higher cytokine production in dendritic cells and MCs with the lowest cytotoxicity at a charge-neutralizing ratio of nitrogen/phosphate = 1 for M7 and CpG. This combination formed spherical NPs approximately 200 nm in diameter with self-assembling capacity. Mice were vaccinated intranasally with COBRA HA and M7-CpG NPs in a prime–boost–boost schedule. Vaccinated mice had significantly higher antigen-specific antibody responses (IgG and IgA) in serum and mucosa compared with controls. Splenocytes from vaccinated mice had significantly increased cytokine production upon antigen recall and the presence of central and effector memory T cells in draining lymph nodes. Finally, co-immunization with NPs and COBRA HA induced influenza H3N2-specific HA inhibition antibody titers across multiple strains and partially protected mice from a challenge against an H3N2 virus. These results illustrate that the M7-CpG NP adjuvant combination can induce a protective immune response with a broadly reactive influenza antigen via mucosal vaccination.
Funder
National Institutes of Health
Subject
Immunology,Immunology and Allergy
Reference77 articles.
1. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: An analysis for the global burden of disease study 2017;Collaborators;Lancet,2019
2. Global burden of influenza-associated lower respiratory tract infections and hospitalizations among adults: A systematic review and meta-analysis;Lafond;PloS Med,2021
3. Rates of influenza-associated hospitalization, intensive care unit admission, and in-hospital death by race and ethnicity in the united states from 2009 to 2019;O'Halloran;JAMA Netw Open,2021
4. Influenza pandemics of the 20th century;Kilbourne;Emerg Infect Dis,2006
5. Metal-organic coordination polymer for delivery of a subunit broadly acting influenza vaccine;Eckshtain-Levi;ACS Appl Mater Interfaces,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献